JRF 102
Alternative Names: JRF-102Latest Information Update: 22 Apr 2021
At a glance
- Originator Chengdu Jinrui Foundation Biotech
- Class Antineoplastics
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Apr 2021 Discontinued - Preclinical for Cancer in China (unspecified route) (Chengdu Jinrui Foundation Biotech pipeline, April 2021)
- 29 Jul 2020 Preclinical trials in Cancer in China (unspecified route), prior to July 2020 (Chengdu Jinrui Foundation Biotech pipeline, July 2020)
- 29 Jul 2020 Chengdu Jinrui Foundation Biotech submits an IND application for Cancer, prior to July 2020 (Chengdu Jinrui Foundation Biotech pipeline, July 2020)